60Q Stock Overview
A biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Captor Therapeutics Spolka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł16.10 |
| 52 Week High | zł31.40 |
| 52 Week Low | zł13.00 |
| Beta | 0.58 |
| 11 Month Change | -2.13% |
| 3 Month Change | -3.88% |
| 1 Year Change | -48.56% |
| 33 Year Change | -60.97% |
| 5 Year Change | n/a |
| Change since IPO | -55.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 60Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -0.9% | 0.6% |
| 1Y | -48.6% | -18.0% | 3.3% |
Return vs Industry: 60Q underperformed the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 60Q underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| 60Q volatility | |
|---|---|
| 60Q Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 60Q has not had significant price volatility in the past 3 months.
Volatility Over Time: 60Q's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 105 | Tom Shepherd | www.captortherapeutics.com |
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage.
Captor Therapeutics Spolka Akcyjna Fundamentals Summary
| 60Q fundamental statistics | |
|---|---|
| Market cap | €79.63m |
| Earnings (TTM) | -€15.32m |
| Revenue (TTM) | €3.76m |
21.2x
P/S Ratio-5.2x
P/E RatioIs 60Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 60Q income statement (TTM) | |
|---|---|
| Revenue | zł16.16m |
| Cost of Revenue | zł7.39m |
| Gross Profit | zł8.78m |
| Other Expenses | zł74.57m |
| Earnings | -zł65.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 05, 2024
| Earnings per share (EPS) | -14.16 |
| Gross Margin | 54.29% |
| Net Profit Margin | -407.07% |
| Debt/Equity Ratio | 0% |
How did 60Q perform over the long term?
See historical performance and comparison